Thermo Fisher completes $1 billion stock repurchase

WALTHAM, Mass. - Thermo Fisher Scientific Inc. (NYSE:TMO), a global leader in serving science, has announced the completion of a $1 billion stock repurchase. The transaction involved the buyback of 1.9 million shares of its common stock. Following this recent repurchase, the company has reported that an additional $3 billion is available for future buybacks under its current share repurchase authorization. According to InvestingPro data, this aligns with management's aggressive share buyback strategy, complementing the company's 7-year streak of consecutive dividend increases.

The completion of this buyback is part of Thermo Fisher's ongoing capital return program, designed to deliver value to its shareholders. Share repurchase programs like this are often used by companies to reinvest in themselves, reduce the number of outstanding shares, and increase the value of remaining shares. With a market capitalization of $204.4 billion and a solid financial health score rated as "GOOD" by InvestingPro, the company demonstrates strong fundamentals supporting its capital return initiatives.

Thermo Fisher Scientific, with last twelve months revenue of $42.37 billion, positions itself as a key player in the science service industry. The company's mission is to support its customers across various sectors, including life sciences research, laboratory productivity, diagnostics, and the development of therapies. Based on InvestingPro analysis, which offers comprehensive research reports for over 1,400 US stocks, the company maintains strong profitability with a 40.7% gross margin and has demonstrated consistent growth with a 12% revenue CAGR over the past five years.

The company's extensive portfolio includes well-known brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD (NASDAQ:PPD). These brands are part of Thermo Fisher's strategy to offer a combination of innovative technologies and services to its global customer base.

The information regarding the share repurchase was based on a press release statement from Thermo Fisher Scientific. The company's stock is traded on the New York Stock Exchange under the ticker symbol TMO. As of today, Thermo Fisher has not provided further details on the timing or structure of future repurchases under the authorization.

Investors and shareholders typically monitor share repurchase announcements closely as they can affect a company's stock price and indicate management's confidence in the company's financial health and future performance. However, the implications of such buybacks on the company's stock value and market performance will unfold over time and are subject to market conditions.

In other recent news, Thermo Fisher Scientific has made notable strides in its financial performance. The company reported a robust third-quarter earnings with a revenue of $10.6 billion and an adjusted earnings per share (EPS) of $5.28. The firm also raised its full-year adjusted EPS guidance to a range of $21.35 to $22.07, while maintaining its revenue forecast within the range of $42.4 billion to $43.3 billion.

In addition, Thermo Fisher announced a new share repurchase program of $4 billion, replacing its previous buyback plan. This strategic move demonstrates the company's commitment to returning value to shareholders. Thermo Fisher also declared a quarterly cash dividend of $0.39 per common share, further extending its shareholder-focused activities.

In terms of analyst insights, Baird adjusted its price target for Thermo Fisher shares to $622 from the previous $632, while maintaining an Outperform rating. This reflects confidence in the company's ability to navigate current market conditions.

These recent developments underline Thermo Fisher's ongoing efforts to meet its long-term goals amid market uncertainties.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.